CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer
Open Access
- 8 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 27 (12), 2875-2883
- https://doi.org/10.1002/stem.236
Abstract
Evidence is accumulating that solid tumors contain a rare phenotypically distinct population of cells, termed cancer stem cells (CSC), which give rise to and maintain the bulk of the tumor. These CSC are thought to be resistant to current chemotherapeutic strategies due to their intrinsic stem-like properties and thus may provide the principal driving force behind recurrent tumor growth. Given the high frequency of recurrent metastasis associated with human ovarian cancer, we sought to determine whether primary human ovarian tumors contain populations of cells with enhanced tumor-initiating capacity, a characteristic of CSC. Using an in vivo serial transplantation model, we show that primary uncultured human ovarian tumors can be reliably propagated in NOD/SCID mice, generating heterogeneous tumors that maintain the histological integrity of the parental tumor. The observed frequency of tumor engraftment suggests only certain subpopulations of ovarian tumor cells have the capacity to recapitulate tumor growth. Further profiling of human ovarian tumors for expression of candidate CSC surface markers indicated consistent expression of CD133. To determine whether CD133 expression could define a tumor-initiating cell population in primary human ovarian tumors, fluorescence-activated cell sorting (FACS) methods were employed. Injection of sorted CD133+ and CD133− cell populations into NOD/SCID mice established that tumor-derived CD133+ cells have an increased tumorigenic capacity and are capable of recapitulating the original heterogeneous tumor. Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer. STEM CELLS 2009;27:2875–2883Funding Information
- Dana Farber/Harvard Cancer Center Ovarian SPORE
- Marsha Rivkin Center for Ovarian Cancer Research
- The Julie Fund
- Advanced Medical Research Foundation
- Ovarian Cancer Research Fund
- Vincent Memorial Research Fund
- Ovarian Cancer and Education Awareness Network
- Robert Lynn v. d. Luft and Christa v. d. Luft
This publication has 26 references indexed in Scilit:
- CD133-Expressing Stem Cells Associated with Ovarian Metastases Establish an Endothelial Hierarchy and Contribute to Tumor VasculatureThe International Journal of Cell Cloning, 2009
- Efficient tumour formation by single human melanoma cellsNature, 2008
- Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human TumorsCancer Research, 2008
- Cancer stem cells – old concepts, new insightsCell Death & Differentiation, 2008
- Phenotypic characterization of human colorectal cancer stem cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular ProfilesCancer Research, 2007
- Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinomaProceedings of the National Academy of Sciences of the United States of America, 2007
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessProceedings of the National Academy of Sciences of the United States of America, 2006
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003